Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 20, 2008

National Neurovision Research Institute to Fund Evaluation of Resolvyx Pharmaceuticals’ Eye Disease Therapeutics

  • National Neurovision Research Institute (NNRI) and Resolvyx Pharmaceuticals inked a research collaboration whereby NNRI will fully fund preclinical studies to evaluate the potential of resolvin therapeutics for eye diseases of the retina that lack current treatments, specifically genetic retinal degenerative diseases and dry age-related macular degeneration (AMD).

    NNRI will fully fund preclinical studies and will also provide access to specialized research facilities and ocular research experts to conduct studies to evaluate the effectiveness of resolvins for specific eye diseases. Resolvyx will provide the company's resolvin therapeutics, including RX-10001, RX-10008, and RX-20001, for the research studies. Resolvyx will retain all rights to develop and commercialize these compounds and any discoveries that result from the collaboration.

    Resolvins are a recently discovered family of naturally occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases, according to Resolvyx. In particular, resolvins act to protect healthy tissue during an immune response to infection, injury, or other environmental challenge, prevent cell death, and then act to resolve inflammation and promote healing after the insult has passed. 

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »